Navigation Links
Genoptix Reports Strong Financial Results for First Quarter 2008
Date:5/8/2008

CARLSBAD, Calif., May 8 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, today reported revenues of $22.3 million for the first quarter ended March 31, 2008, as compared to revenues of $10.7 million for the comparable period in 2007. The first quarter 2008 results include a $651 thousand benefit from changes in accounting estimates relating to 2007.

"We started the year with another quarter of strong operational results, increasing sales by 20% over the fourth quarter of 2007 and 109% from a year ago," said Tina Nova Bennett, Ph.D., President and CEO of Genoptix. "A growing customer base and improving case volumes continue to drive revenues as customer adoption of our services grows in regions across the country."

The Company also reported GAAP net income of $5.0 million for the first quarter ended March 31, 2008, compared to net income of $1.3 million for the first quarter ended March 31, 2007. Diluted earnings per share, or EPS, for the first quarter of 2008 was $0.29 based on 17.5 million weighted average common shares outstanding, including $0.05 of negative impact from increased costs associated with non-cash stock-based compensation expense, which includes the launch of our employee stock purchase program at the start of 2008.

The Company completed its initial public offering, or IPO, on November 2, 2007. On a pro forma basis, assuming conversion of all outstanding preferred stock, diluted EPS for the three months ended March 31, 2007 would have been $0.10 (see "Pro Forma Net Income Per Share" table below).

Gross profit for the first quarter of 2008 improved to $13.1 million, or 59% of revenues, from $6.0 million, or 56% of revenues, for the first quarter
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. Genoptix Announces Pricing of Secondary Public Offering
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
9. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
10. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
11. Haemacure Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... ANGELES (PRWEB) May 27, 2015 Readers ... processes may find help in author Chester Litvin ... Psychoconduction : Litvin’s Code” (published by Trafford Publishing). , ... new approach for stimulating the brain. This book will ... to reeducate their sensory brain cells . He ...
(Date:5/26/2015)... May 27, 2015 This summer, ChopChop: ... with local communities at key events in Greater Boston with ... with free copies of ChopChop Magazine, healthy snacks and other ... stay active. , “We want to get our message of ... in a memorable and fun way,” explains Sally Sampson, Founder ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 In God’s ... with her as she writes an unforgettable story of ... in her life. The first black student to desegregate ... and beaten by some students, treated harshly by a ... A motivating personal phone conversation with Dr. Martin Luther ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Dermatologic surgeons ... in 2014, according to survey results released today by ... in skin cancer treatments and several cosmetic categories, 2014 ... but remained steady overall compared to 2013 figures. ... cancer treatments ranked as the most-performed procedure (3.08 million) ...
(Date:5/26/2015)... 2015 The federal court overseeing more ... behalf of individuals who were allegedly injured by the ... Science Day. According to an Order issued in the ... 21st, topics to be addressed include Xarelto adverse events, ... blood test based testing with Xarelto, and Xarelto pharmacology. ...
Breaking Medicine News(10 mins):Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 3Health News:Award-Winning Cooking Magazine for Kids Takes Healthy Cooking and Eating to the Streets with One-of-a-Kind Bike Campaign 2Health News:Grace Sibley Releases Second Book, God's Unstoppable Favor 2Health News:New ASDS Survey: 9.5 Million Treatments Performed in 2014 2Health News:New ASDS Survey: 9.5 Million Treatments Performed in 2014 3Health News:New ASDS Survey: 9.5 Million Treatments Performed in 2014 4Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 2Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 3Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 4
... State ... Medical Center ... Clinical Trial TUSTIN, Calif. and SYDNEY, April 22 ... heart assist technologies, announced today that The Ohio State University Medical ...
... Parks to hold second annual Walk-a-thon event THIS SUMMERNEW YORK, ... Six Flags, and Cure Kids Cancer have teamed up once ... its "A Walk In The Park" program. This unique ... properties April 26 through July 26 offering local neighborhoods a ...
... Smokefree Laws, Three plus DC Raised Tobacco Taxes--WASHINGTON, April 22 ... Lung Association, 2008 proved to be a slow year for ... select few taking the steps that are needed to curb ... update of State Legislated Actions on Tobacco Issues ...
... BILTHOVEN and NIJMEGEN, The Netherlands, April 22 ... Medical Centre have entered,into a research agreement ... , Under the ... Experimental Urology), InteRNA,s unique lentiviral-based miRNA,overexpression library ...
... a week, , , WEDNESDAY, April 22 (HealthDay News) -- Men ... to have a reduced risk of heart failure, a new ... Swedish researchers followed nearly 40,000 Swedish men, ages 45 to ... outcomes. During that time, 597 men with no history of ...
... Together to Ask President Obama for a Greater Voice in the ... ... April 22, 2009 -- In recent days, both conservative and liberal ... in the healthcare reform debate. Understanding that President Obama has ...
Cached Medicine News:Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 2Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 3Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 4Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 2Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 3Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 4Health News:New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies 2Health News:New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies 3Health News:InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer 2Health News:Fatty Fish May Cut Heart Failure Risk in Men 2Health News:Millennials Push For Seat at the Table on Healthcare Reform 2
(Date:5/26/2015)... , May 26, 2015  AbbVie (NYSE: ... Phase 3 GIFT-I study of its investigational, all-oral, ... treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of ... Japan . 1 GIFT-I evaluated ... infected Japanese patients, with and without cirrhosis, who ...
(Date:5/26/2015)... -- XRpro Sciences, Inc., a provider of a unique platform for ... and ion channel assays for the pharmaceutical industry, announced today ... MicroCap Conference on Thursday, May 28, 2015 in ... Hotel. The Company,s presentation by Richie Cunningham ... to begin at 1:30 p.m ET. Click here to view ...
(Date:5/26/2015)... , England and PITTSBURGH , May 26, ... leading global pharmaceutical company, today announced that Mylan CEO ... Bernstein Strategic Decisions Conference, Friday, May 29, 2015 at ... access a live webcast of the presentation via the ... . An archived version will also be available following ...
Breaking Medicine Technology:AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6XRpro Sciences, Inc. To Present at 2015 Marcum MicroCap Conference 2
... Families of Spinal Muscular Atrophy announced today that Repligen ... Administration to commence a Phase I safety study in healthy ... for Spinal Muscular Atrophy. FSMA began the ... drug development, when risk is the highest.  It was the ...
... BD (Becton, Dickinson and Company) (NYSE: ... today the publication of its 2010 Sustainability Report ... dedicated associates worldwide to pursuing the Company,s purpose, " ... so in a way that is centered on balancing ...
Cached Medicine Technology:Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA 2Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA 3BD Issues 2010 Sustainability Report 2BD Issues 2010 Sustainability Report 3
... The High Throughput Sorter RSD ... high volume laboratories in the field ... is not only of considerable speed ... optional Recapping Module can be integrated. ...
... System RCS 800 closes various plastic primary and ... way. Different tube heights and diameters can be ... be used for send-outs. The integration into other ... System RSD 800 and High Throughput Sorter RSD ...
... Decapping System DS 800 selectively removes closures from ... the barcode towards the rack opening in one ... integrated in PVT Systems like Sorting System RS ... Sorter RSD ProVolume and Aliquoting System RSD 800A. ...
... Nanogen offers reagents to detect sequences ... parainfluenza virus 1, 2 and 3; ... respiratory syncytial virus A and B. ... to create homebrew tests., ...
Medicine Products: